Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Nycomed’s decision to be sold up to owners, it is claimed

Nycomed’s decision to be sold up to owners, it is claimed

25th March 2009

Nycomed’s possible sale is up to the owners of the company, it has been claimed.

Earlier this week, the Wall Street Journal reported that the privately-owned Swiss drugmaker had hired Goldman Sachs to look into the option of putting the firm on the market.

The business is looking for potential buyers in a transaction that could be worth up to ten billion euros (9.18 billion pounds), according to the newspaper.

Beatrix Benz, a spokesperson from the drugmaker, told Reuters the company had received a lot of proposals, all of which it was considering.

“The decision for selling Nycomed or an IPO (initial public offering) would have to be taken by our owners,” she commented.

Ms Benz further noted that the company was looking for a partner to assist with the development of its experimental lung called Daxas, concluding there had been much interest.

Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use passed a positive opinion on Nycomed’s Pantozol.

The drug is intended for the short-term treatment of reflux symptoms in adults.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.